Table 1.
Parameters of the HPLC gradient used to separate tamoxifen and its metabolites on a ZORBAX Eclipse XDB-C18 column (150 mm x 2.1 mm I.D., 3.5 μm) at 40°C.
Table 2.
HPLC and MS parameters used to discriminate glucuronide tamoxifen metabolites.
Table 3.
UGT1A4, UGT2B7, UGT2B15 and UGT2B17 genotype frequencies. International codes for SNPs between brackets.
Table 4.
UGT1A4, UGT2B7, UGT2B15 and UGT2B17 allele frequencies. International codes for SNPs provided in brackets.
Table 5.
Concentrations (ng/mL) of tamoxifen metabolites (means (±SD), medians (in cursive) and ranges (in brackets)) detected in patients according to their UGT1A4, UGT2B7, UGT2B15 and UGT2B17 genotypes.
Fig 1.
Concentrations of tamoxifen metabolites (means ± standard deviations, ng/mL) by UGT1A4Leu48Val and UGT2B17del genotype subgroups established according to wt allele doses.
Sample sizes indicated in brackets.
Fig 2.
Concentrations of tamoxifen metabolites (mean ± standard deviation, ng/mL) by UGT2B15Lys523Thr and UGT2B7His268Tyr genotype subgroups established according to wt allele doses.
Sample sizes indicated in brackets.